208 related articles for article (PubMed ID: 24838231)
21. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W
Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409
[TBL] [Abstract][Full Text] [Related]
22. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.
Lu Q; Wang L; Zhang Y; Yu X; Wang C; Wang H; Yang Y; Chong X; Xia T; Meng Y; Wang Y; Lu C; Zhou L; Li B
Oncotarget; 2016 Oct; 7(41):67129-67141. PubMed ID: 27564098
[TBL] [Abstract][Full Text] [Related]
23. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
24. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
25. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
[TBL] [Abstract][Full Text] [Related]
26. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
27. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
28. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
30. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
31. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
32. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
33. Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer.
Yang Y; Guo R; Tian X; Zhang Z; Zhang P; Li C; Feng Z
Biochem Biophys Res Commun; 2017 Aug; 489(4):523-527. PubMed ID: 28579432
[TBL] [Abstract][Full Text] [Related]
34. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Ritter CA; Perez-Torres M; Rinehart C; Guix M; Dugger T; Engelman JA; Arteaga CL
Clin Cancer Res; 2007 Aug; 13(16):4909-19. PubMed ID: 17699871
[TBL] [Abstract][Full Text] [Related]
35. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
36. Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models.
Shiravi F; Mohammadi M; Golsaz-Shirazi F; Bahadori T; Judaki MA; Fatemi F; Zare HA; Haghighat FN; Mobini M; Jeddi-Tehrani M; Amiri MM; Shokri F
Invest New Drugs; 2021 Jun; 39(3):697-704. PubMed ID: 33389387
[TBL] [Abstract][Full Text] [Related]
37. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
39. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
40. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]